US medical technology giant Boston Scientific Corporation (NYSE: BSX) released its Q1 2025 financial report, showing a 20.9% year-on-year (YOY) increase in net sales to USD 4.463 billion. The results reflect strong performance across key business segments and geographic markets.
Business Unit Performance
The MedSurg division reported sales of USD 1.577 billion, a 11.7% YOY increase. Cardiology division sales reached USD 3.085 billion, up 26.2% YOY. These results highlight the company’s robust growth in critical areas of its business.
Geographic Market Highlights
Geographically, sales in the US market surged by 31.1% to USD 2.96 billion. Europe, the Middle East, and Africa (EMEA) saw a 5.5% increase to USD 846 million. The Asia Pacific (APAC) region, Latin America and Canada (LACA), and Emerging Markets also showed growth, with increases of 8.2%, 4.4%, and 6.5% to USD 701 million, USD 155 million, and USD 690 million, respectively.
Acquisitions and Future Outlook
During the quarter, Boston Scientific completed its acquisition of Bolt Medical, Inc., gaining a laser therapy platform for coronary and peripheral artery disease. The company also announced plans to acquire SoniVie Ltd., a developer of the TIVUS intravascular ultrasound system for hypertension management. These strategic moves underscore the company’s commitment to expanding its portfolio in interventional medicine.-Fineline Info & Tech
